Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587178 | 0.81 | IDO1 (0.61) | CYP3A4TDP1MEN1KMT2ACYP1A2 | |
| SCHEMBL29793891 | 0.81 | IDO1 (0.61) | CYP3A4TDP1MEN1KMT2ACYP1A2 | |
| SCHEMBL12841362 | 0.71 | RAB9A (0.44) | TDP1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5859161 | 0.71 | GAA (0.52) | TDP1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29946847 | 0.71 | GAA (0.52) | TDP1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL30538064 | 0.67 | NOTUM (0.42) | TDP1MEN1KMT2AALDH1A1PTGS1 | |
| SCHEMBL17361199 | 0.67 | CYP3A4 (0.54) | CYP3A4TDP1MEN1KMT2ACYP1A2 | |
| SCHEMBL31408101 | 0.65 | IDO1 (0.73) | CYP3A4TDP1MEN1KMT2ACYP1A2 | |
| SCHEMBL16382293 | 0.65 | IDO1 (0.73) | CYP3A4TDP1MEN1KMT2ACYP1A2 | |
| SCHEMBL28832456 | 0.64 | CYP3A4 (0.51) | CYP3A4TDP1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | CYP3A4 1107/4885TDP1 719/4885MEN1 4087/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | CYP3A4 1037/4885TDP1 1755/4885MEN1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.